Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hoth Therapeutics Inc HOTH

Healthcare
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s... see more

Recent & Breaking News (NDAQ:HOTH)

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

PR Newswire 7 days ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

PR Newswire October 29, 2024

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

PR Newswire October 15, 2024

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

PR Newswire September 17, 2024

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

PR Newswire September 5, 2024

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

PR Newswire September 5, 2024

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

PR Newswire August 15, 2024

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

PR Newswire July 24, 2024

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

PR Newswire July 16, 2024

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

PR Newswire June 10, 2024

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

PR Newswire May 1, 2024

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

PR Newswire March 27, 2024

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

PR Newswire March 27, 2024

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

PR Newswire March 19, 2024

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

PR Newswire February 29, 2024

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

PR Newswire February 26, 2024

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

PR Newswire February 13, 2024

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

PR Newswire January 18, 2024

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami

PR Newswire December 27, 2023

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

PR Newswire December 5, 2023